Newsletter | June 30, 2021

06.30.21 -- Life Sciences CEOs Assess Upcoming Business Risk

When Your Next Job Is A Step Back From Where You Were, How Do You Manage, And What Have Been Some Of The Valuable Lessons/Insights Gained From The Experience?

See the answer from Brandi Simpson, former board chair of BioUtah and CEO of Navigen, and now a VP of business and corporate development at Voyager Therapeutics.

Life Sciences CEOs Assess Upcoming Business Risk

We take a closer look at the data related to organizational growth risks included in a recent KPMG “Global CEO Outlook” survey.

How To Identify Capital To Fund Life Sciences Growth

For life sciences companies, funding needs evolve at every stage of growth — creating both challenges and opportunities. Regardless of the stage, it is fundamental to align your funding strategy with your company’s vision.

The Benefits Of Pharma 4.0 And Validation 4.0

Validation 4.0 is an innovative approach to ensuring that the new technologies of Pharma 4.0 are implemented and validated to ensure requirements related to patient safety and product quality are met.

Companies To Watch: IM Therapeutics

Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.

029: The Effects Of Politics On Pharma

According to Outsourced Pharma chief editor Louis Garguilo, “Politics has never played a bigger role in our (global) biopharma industry.” In this episode, we talk with Louis about three of his recent editorials that touch on this subject while also discussing the current IP debate in pharma and the origins of the coronavirus.

June 2021 Digital Edition

Inside you will find more on:

  • Leadership Lessons
  • Drug Development Trends
  • AI In Pharma
  • Supply Chain Strategies

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.